RT Journal Article
T1 Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 48 weeks.
A1 Pérez-Stachowski, Javier
A1 Tortajada, Begoña
A1 Del Arco, Alfonso
A1 Márquez, Efrén
A1 De la Torre, Javier
A1 Nieto, Miriam
A1 García de Lomas, José María
A1 Prada, José Luis
A1 García-Alegría, Javier
A1 Olalla, Julián
K1 Dolutegravir
K1 HIV
K1 antiretroviral treatment
K1 drugs
K1 generic
K1 switch
AB Introduction: Generic drugs are helpful to enhance the efficiency of the sanitary system. A generic coformulation of abacavir (ABC) and lamivudine (3TC) is available since 2016 in Spain. A report of our experience with its use is exposed. Methods: Patients between February 2017 and June 2017 who were taking Triumeq® were switched to the generic ABC + 3TC plus DTG. Efficacy, safety, reasons for discontinuation and costs savings were evaluated at 48 weeks. Results: Switch was made in 93 patients, with a median age of 47 years and a mean time of 12.33 years with HIV infection. Six patients (6.5%) discontinued the new ART, being toxicity of the central nervous system the most frequent reason. The effective saving derived from the change after 1 year of treatment was 151.127 €. Conclusions: The change from Triumeq® to a generic regimen of ABC + 3TC and another pill of DTG seems to be safe and efficient at 48 weeks.
YR 2019
FD 2019-07-05
LK https://hdl.handle.net/10668/26684
UL https://hdl.handle.net/10668/26684
LA en
DS RISalud
RD Apr 6, 2025